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Edited by Veli-Pekka LehtoAbstract This study was designed to determine the molecular
mechanisms underlying the anti-proliferative eﬀect of the endo-
cannabinoid anandamide on highly invasive human breast cancer
cells, MDA-MB-231. We show that a metabolically stable ana-
logue of anandamide, Met-F-AEA, induces an S phase growth
arrest correlated with Chk1 activation, Cdc25A degradation
and suppression of Cdk2 activity. These ﬁndings demonstrate
that Met-F-AEA induced cell cycle blockade relies on modulated
expression and activity of key S phase regulatory proteins. The
observed mechanism of action, already reported for well-known
chemotherapeutic drugs, provides strong evidence for a direct
role of anandamide related compounds in the activation of cell
cycle checkpoints.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The endogenous cannabinoid system, comprising the can-
nabinoid receptors CB1 and CB2, their endogenous ligands
(endocannabinoids) and proteins that regulate endocannabi-
noid biosynthesis and degradation, controls several physiolog-
ical and pathological conditions. Recent evidence indicates
that endocannabinoids inﬂuence the intracellular events con-
trolling the proliferation and apoptosis of a number of cancer
cell types, thereby leading to anti-tumour eﬀects both in vitro
and in vivo [1]. The endogenous cannabinoid anandamide has
been found to exert not only anti-proliferative but also pro-
apoptotic eﬀects in various cancer cells [2]. The inhibitory ef-
fect of anandamide on the proliferation of cancer cells appears
to be mediated via its interaction with the transmembrane CB1
cannabinoid receptor subtype. We previously observed thatAbbreviations: CB1, cannabinoid receptor 1; CB2, cannabinoid recep-
tor 2; Met-F-AEA, 2-methyl-arachidonoyl-20-F-ethylamide; Rb, reti-
noblastoma; Cdk, cyclin dependent kinase; CKIs, cdk inhibitors; HU,
hydroxyurea
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doi:10.1016/j.febslet.2006.09.074anandamide inhibits the proliferation of PRL-responsive
human breast cancer cells through the downregulation of the
long form of the PRL receptor (PRLr). Furthermore, we dem-
onstrated that anandamide dose-dependently inhibited the
proliferation of MCF-7 and EFM-19 breast cancer cells in
the range of lM concentration, while the proliferation of sev-
eral other non-mammary cancer cell lines was not aﬀected at
the same dose [3]. In these cell lines the anti-proliferative eﬀect
of anandamide was not due to toxicity or to apoptosis but was
accompanied by a reduction of cells in the S phase of the cell
cycle [3,4]. Moreover, CB1 receptor activation is also able to
induce cell cycle arrest of thyroid epithelioma cells (KiMol
cells, obtained by the transformation of FRTL-5 with the
K-ras oncogene), in G0/G1 phase of cell cycle [5,6]. Recently,
we described that 2-methyl-2 0-F-anandamide (Met-F-AEA),
a stable analogue of anandamide, inhibits cell proliferation
of MDA-MB-231 in a dose-dependent manner, but the molec-
ular mechanism at the basis of this eﬀect is yet unknown [7]. In
the present study, we examined the Met-F-AEA eﬀect on
cell-cycle progression and on the expression of a variety of
molecules involved in cycle control. Cell-cycle progression is
regulated by the sequential activation and subsequent inactiva-
tion of a family of cyclin-dependent protein kinases (Cdks).
The active forms of these kinases are heterodimers with a reg-
ulatory subunit known as cyclin. A critical target of Cdk activ-
ity is the retinoblastoma susceptibility gene product (Rb).
Phosphorylation of Rb by cdk activity results in the release
of E2F-DP1 heterodimeric transcription factors that transcribe
genes essential for G1/S progression, such as cyclins A and E.
The activation of Cdks depends upon multiple levels of regula-
tion: the synthesis of the cyclins and their assembly into active
cyclin/Cdk complexes, the phosphorylation of the Cdks, and
the inhibitory action of the Cdk inhibitors (CKIs) in these
complexes. The CKIs appear to be the most diverse and ﬂexi-
ble regulators. Among them, p21waf and p27kip1 bind to all the
Cdk complexes and preferentially inhibit the ones containing
Cdk2 [8–12].
Eukaryotic cells actively slow their progression through S
phase when their DNA is damaged. The biological importance
of this response, which is called the intra-S-phase checkpoint,
is not clear, but it is frequently assumed that this checkpoint
provides cells with time to repair the damaged DNA before
its replication [13]. Most, if not all, of the intra-S-phase check-
point pathways are downstream of the ATR family and de-
pend on the Chk family of protein kinases (Chk1 and Chk2),
that become active when they are phosphorylated by an
ATR-family kinase [14]. One of the principal targets of theblished by Elsevier B.V. All rights reserved.
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tyrosine 15 (Tyr-15) and activated by removal of the phos-
phate at Tyr-15. Cdc25A is the phosphatase that activates
Cdk2. Phosphorylation of Cdc25A by Chk1 leads to its degra-
dation, thus phosphorylated Cdc25A cannot dephosphorylate
and activate Cdk2 [15]. In particular Cdc25A is involved in S
phase, activating cyclin E-Cdk2 and cyclin A-Cdk2 complexes,
that are required for initiation of DNA replication. Thus inac-
tivation of Cdk2 could slow S phase by reducing the rate of ini-
tiation at origins [16].
In this study, we reported that Met-F-AEA treatment of
MDA-MB-231 cells results in growth arrest characterized by
an accumulation in the S phase of the cell cycle with a concom-
itant decrease of the percentage of cells in G2/M phase. Fur-
thermore, our results provide evidence that Met-F-AEA
induces Cdc25A degradation through activation of Chk1 and
subsequent inhibition of Cdk2 activity. This could be one of
the possible mechanisms by means of which inhibition of
Cdk2 may slow S phase.2. Materials and methods
2.1. Drugs
Met-F-AEA, staurosporine and hydroxyurea were purchased from
Sigma (St. Louis, MO). SR141716 was kindly provided by Sanoﬁ-
Aventis.
2.2. Cell culture
The human breast carcinoma cell line MDA-MB-231 was main-
tained in RPMI 1640 medium (Gibco BRL Life technologies, MD)
supplemented with 10% inactivated fetal bovine serum and 2 mM L-
glutamine. Cells were cultured in a humidiﬁed environment containing
5% CO2 and held at a constant temperature of 37 C.2.3. Cell cycle synchronization and ﬂow cytometry analysis
To synchronize cells at the G1/S interface, they were incubated in
medium without serum containing 2 mM hydroxyurea for 12 h, as
previously described [17]. The distribution of cells among the diﬀerent
phases of the cell cycle was evaluated by ﬂow cytometry analysis of
the DNA content. Cells (5 · 105) were collected, washed twice with
PBS, ﬁxed by ethanol 70% and kept at 20 C for at least 4 h.
Propidium iodide (10 lg/ml) in PBS containing 100 U/ml DNAse-
free RNAse was added to the cells for 15 min at room temperature
[18].
Cells were acquired by a FACSalibur ﬂow cytometer (BD Biosci-
ences) and then analysis was performed using ModFit LT v3.0 from
Verity Software House, Inc. (Topsham, ME); 10000 events were col-
lected, corrected for debris and aggregate populations.2.4. Antibodies
The anti-pRb (sc-50), cyclin E, cyclin A, p27Kip1 (sc-528), and p21waf
(sc-756), Cdk2, cdc25A antibodies were from Santa Cruz Biotechnol-
ogy, Inc. The anti-pChk1 (S345) was from Cell Signaling Technology,
Inc. (Danvers, MA).2.5. Immunoprecipitation
Cells treated with Met-F-AEA at various times were lysed at 4 C in
lysis buﬀer (50 mM Tris, pH 7.4; 150 mM NaCl; 20 mM EDTA; 0.5%
NP-40; 10 mg/ml phenylmethylsulfonyl ﬂuoride; 0.1 UI/ml of aproti-
nin; 1 mM sodium orthovanadate), and centrifugated (15000 · g for
10 min at 4 C). Equivalent amounts of protein were then incubated
with 1 mg of antibodies against Cdk2 for 1 h at 4 C. The immune
complexes were bound to protein A–agarose (Sigma) for 1 h at 4 C,
and then collected by centrifugation. Proteins (50 lg) were eluted with
Laemmly sample buﬀer (5 min at 95 C), analyzed by PAGE in the
presence of SDS and transferred to nitrocellulose membranes (Amer-
sham, Aylesbury, UK).2.6. Western blot analysis
Cell lysates were obtained and processed for Western blot analysis as
previously described [7]. Immunoreactive bands were quantiﬁed using
Quantity One 1-D analysis software (Bio-Rad).
2.7. Protein kinase activity
After immunoprecipitation with the antibody directed against anti-
Cdk2, the precipitates were incubated with histone H1 (5 lg/ml) in
the presence of 5 lCi [c-32P]ATP (4500 Ci/mmol), 100 lM ATP for
15 min at 30 C. The phosphorylated histone H1 was separated by
electrophoresis in SDS–12.5% polyacrylamide gel and visualized by
autoradiography, and the incorporated radioactivity was quantiﬁed
by scintillation counting [19].
2.8. Statistical analysis
All data were presented as means ± S.E. Statistical analysis was per-
formed using one-way ANOVA. A P value less to 0.05 was considered
statistically signiﬁcant.3. Results
3.1. Eﬀect of Met-F-AEA treatment on cell cycle distribution of
MDA-MB-231
We previously observed that Met-F-AEA treatment of
MDA-MB-231 breast cancer cell line caused the inhibition of
cell growth in a dose-dependent manner and this eﬀect was
not caused by necrosis or apoptosis [7] (Fig. 1A). To further
investigate the nature of growth inhibition by Met-F-AEA,
the cell cycle phase distribution was assessed by ﬂow cytome-
try. Exponentially growing MDA-MB-231 cells, incubated
for 24 h with 10 lM Met-F-AEA, accumulated in the S phase
of the cell cycle (Fig. 1B). To analyze the eﬀect of Met-F-AEA
on cell cycle progression in more detail, MDA-MB-231 cells
were synchronized in late G1-S phase by hydroxyurea (HU,
2 mM). The cell cycle distribution was analyzed when cells
were released from this blockade with complete medium in
the presence or absence of Met-F-AEA. As shown in Fig. 1C
after removal of hydroxyurea these cells were synchronized
with 76.35% of the population containing a G1 phase DNA
content. By 6 h, 90% of control cells were in S phase, by
12 h the majority (70,8%) were in G2/M phase and then they
underwent mitosis and entered the next cell cycle division.
When cells were treated with Met-F-AEA after release re-
mained longer in G1 phase, by 6 h, 23.48% of the cells were
in this phase and were delayed in their progression to S phase
in all time points, compared to control cells. By 24 h, approx-
imately 83.83% of the treated cells were arrested in S phase.
Removal of Met-F-AEA from the culture medium after fur-
ther 24 h led to reversibility of the cytostatic eﬀect; in fact
the kinetics of cell cycle overlapped in both untreated and trea-
ted cells (data not shown), moreover pre-treatment with the
CB1 receptor selective antagonist SR141716 (30 min, 0.1 lM)
before Met-F-AEA exposure (24 h, 10 lM) prevented the S-
phase blockade, suggesting a CB1 receptor dependent signal-
ing pathway (Fig. 1D).
3.2. Eﬀect of Met-F-AEA on cell cycle regulators
In order to examine the eﬀects of Met-F-AEA on the expres-
sion of proteins regulating cell cycle progression, we performed
Western blot analysis of total cell lysates (40 c/sample) at three
time points following the release from hydroxyurea blockade
(6, 12, 24 h). Given the role of the CKI family of proteins in
enforcing cell cycle arrest we initially analyzed the protein level
Fig. 1. Eﬀect of Met-F-AEA treatment on cell cycle distribution of MDA-MB-231. (A) Chemical structure of Met-F-AEA (2-methyl-arachidonoyl-
2 0-F-ethylamide) that is an analogue of anandamide in which the alcohol of the ethanolamide group has been removed and replaced with a ﬂuorine
atom, and an a-methyl group has been added to the C-2 position of arachidonic acid [39]. (B) Exponentially growing MDA-MB-231 cells were
treated or not (control) for 24 h with Met-F-AEA (10 lM). After 24 h the cell populations were harvested and prepared for ﬂow cytometry analysis
as described in Section 2. In the graphs are reported the percentage of cells in each phase of cell cycle, with SE in parentheses. Graphs are
representative of three independent experiments with similar results. (C) Cells arrested at G1/S interphase by incubation with hydroxyurea (2 mM for
12 h) were released at t = 0 in the absence (control) or in the presence of Met-F-AEA (10 lM). The cells were collected at times indicated and their
DNA contents were analyzed by ﬂow cytometry. Graphs are representative of two independent experiments with similar results. (D) Synchronized
cells were cultured for 24 h in fresh medium (control) or pre-treated with the CB1 receptor antagonist SR141716 (30 min, 0.1 lM) before Met-F-AEA
exposure (24 h, 10 lM). The cells were harvested and prepared for ﬂow cytometry analysis. Graphs are representative of three independent
experiments with similar results.
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crease of p27kip1 and p21waf protein levels in a time-dependent
manner with a remarkable eﬀect at 24 h of treatment (Fig. 2).
Next we observed that Met-F-AEA treatment decreased the
expression levels of cyclins A and E especially at 24 h com-
pared to control cells. There was no signiﬁcant change in the
protein levels of cyclin B1, cyclin D1, Cdk4 and Cdk6 (data
not shown). Reprobing of the membranes with anti-actin anti-
body conﬁrmed equal protein loading in each case.3.3. Eﬀect of Met-F-AEA on Cdk2 activity
Since cyclins E and A levels were decreased in Met-F-AEA
treated cells at 24 h and since Cdk2, activated by the interac-
tion with cyclin E in late G1 phase and cyclin A in S phase,
determines the ability of cells to enter into, and progress
through S phase, we assayed cell lysates for Cdk2 kinase activ-
ity at 24 h from Met-F-AEA exposure. Cdk2 protein com-
plexes were immunoprecipitated from total cell lysates by
using a Cdk2-speciﬁc antibody, and half of each sample was
Fig. 2. Eﬀect of Met-F-AEA on the expression of components of the
cell cycle machinery. Cells synchronized at G1/S interphase by
hydroxyurea (2 mM for 12 h) were released in cycle and incubated in
presence or absence of Met-F-AEA (10 lM) for 6, 12 and 24 h. Cells
were harvested at times indicated and analyzed by Western blotting
with antibodies against p21waf, p27kip1, cyclin A and cyclin E as shown.
Same ﬁlters were stripped and reprobed with rabbit polyclonal anti-
actin antibody. Immunoreactive bands were quantiﬁed using Quantity
One program. The diagram shows quantiﬁcation of the intensity of
bands, calibrated to the intensity of the actin bands, expressed as
mean ± S.E. (*P < 0.01 for Met-F-AEA vs vehicle). Each experiment
was repeated at least three times. The ﬁgure shows a representative
blot.
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phosphorylate histone H1 [19], while the other half was ana-Fig. 3. (A) Eﬀect of Met-F-AEA on Cdk2 kinase activity. Synchronized cells
the lysates were immunoprecipitated with anti-Cdk2 antibody. The kinase a
substrate. The amounts of Cdk2 and Cyclin E into immunocomplexes were
bands were quantiﬁed using Quantity One program. The diagram shows qu
Cdk2 bands, expressed as mean ± S.E. (*P < 0.05 for Met-F-AEA vs CTR). E
AEA on Rb phosphorylation. Total cell lysates were subjected to Western blo
hyperphosphorylated forms. Actin was used as loading control.lyzed for Cdk2 protein expression by Western blot. The treat-
ment of synchronized cells with Met-F-AEA (10 lM) for 24 h
caused a severe reduction in the ability of Cdk2 to phosphor-
ylate histone H1 as compared to control cells (Fig. 3A). Of
note, Met-F-AEA did not alter the total level of Cdk2 protein
in the immunoprecipitates of treated and untreated samples
(Fig. 3A). In order to verify the interaction of cyclin E
with Cdk2 we performed an immunoblotting analysis of the
immunoprecipitates. We observed that cyclin E is associated
with Cdk2 and the levels of cyclin E were decreased in
Met-F-AEA treated samples compared to control samples
(Fig. 3A). Moreover, also p27kip1 and p21waf were present in
the immunoprecipitated complexes and their levels were
augmented in Met-F-AEA treated samples (Fig. 3A). Since cy-
clin E complexes with Cdk2 to further phosphorylate retino-
blastoma protein, an important checkpoint of cell cycle
progression, we examined the phosphorylation status of Rb
in Met-F-AEA treated and control cells at three time points.
While in control cells Rb is readily hyperphosphorylated, in
Met-F-AEA treated cells, at 24 h is hypophosphorylated
(Fig. 3B). This ﬁnding is consistent with the Met-F-AEA in-
duced Cdk2 inhibition at the same time (24 h) and with the
failure of the cells to progress through the cell cycle. Interest-
ingly, although Met-F-AEA did not aﬀected cyclin D1/Cdk4
expression, a reduction in Rb phosphorylation at S780, the res-
idue speciﬁcally targeted by cyclin D1/Cdk4 complexes [40],
was also found in Met-F-AEA treated cells (Fig. 3B).
3.4. Met-F-AEA causes Chk1 phosphorylation and Cdc25A
degradation
We speculated that the arrest of cell cycle progression in S
phase induced by Met-F-AEA might be related to the activa-
tion of an intra S-phase checkpoint. In order to investigate this
hypothesis, we treated MDA-MB-231 cells with Met-F-AEA
for three time points and immunoblotted the cell lysates forwere treated or not with Met-F-AEA 10 lM for 24 h. After incubation
ctivity of Cdk2 immunocomplexes was measured with histone H1 as
analyzed by Western blotting by speciﬁc antibodies. Immunoreactive
antiﬁcation of the intensity of bands, calibrated to the intensity of the
ach experiment was repeated at least three times. (B) Eﬀect of Met-F-
t analysis for Rb. Hypophosphorylated forms of Rb migrate faster than
Fig. 4. (A) Met-F-AEA causes Chk1 phosphorylation and Cdc25A degradation. In the upper panel: synchronized cells were treated or not with Met-
F-AEA for 6, 12 and 24 h. After treatment cell lysates were blotted with phospho-Chk1 (Ser-345) antibody. The level of the phosphorylated protein
was normalized to the level of the total protein, reprobing the membrane with anti-Chk1 protein. In the lower panel: synchronized cells were treated
with Met-F-AEA for the same time and analyzed by Western blot with anti-Cdc25A antibody. Actin was used as loading control. (B) Inhibition of
Chk1 activity by staurosporine (8 nM) for 24 h. Synchronized cells were treated with Met-F-AEA (1) or without (ctr); staurosporine (2) and Met-F-
AEA in the presence of staurosporine (3) for 24 h, harvested and processed for Western blotting with phospho (S345)-Chk1 (upper panel) and
Cdc25A antibodies (lower panel). Filters were stripped and reprobed with Chk1 and actin antibodies as control. Immunoreactive bands (A and B)
were quantiﬁed using Quantity One program. The diagrams show quantiﬁcation of the intensity of bands, calibrated to the intensity of the Chk1
bands (upper panel A and B) and of actin bands (lower panel A and B), expressed as means ± S.E. (*P < 0.01 for Met-F-AEA vs ctr, for HU vs ctr
and for staurosporine or Met-F-AEA + staurosporine vs Met-F-AEA). Each experiment was repeated at least three times. The ﬁgure shows a
representative blot.
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a control, we also treated the cells with hydroxyurea, a DNA
synthesis inhibitor, that is known to induce Chk1 phosphory-
lation and activation [21]. Phosphorylation of Chk1 was ob-
served in cells treated with Met-F-AEA as soon as 6 h,
indicating a rapid induction of the Chk1 pathway. At 24 h time
point we observed a signiﬁcant increase in the protein levels of
phosphorylated Chk1 [22–24], although the amount of Chk1
protein remained constant before and after drug treatment
(Fig. 4A). To investigate whether Chk1 phosphorylation in-
duced by Met-F-AEA treatment results in Chk1 activation,
we analyzed the stability of Cdc25A protein in the same sam-
ples. Chk1 phosphorylation leads to a decreased Cdc25A
abundance starting at 12 h time point and a complete degrada-
tion at 24 h (Fig. 4A), indicating that Met-F-AEA not only
confers Chk1 phosphorylation but also Chk1 activation. To
ascertain whether Chk1 phosphorylation mediates Met-F-
AEA induced Cdc25A degradation, we treated MDA-MB-
231 cells with Met-F-AEA in presence of a Chk1 inhibitor,
staurosporine [25], at 8 nM for 24 h. As shown in Fig. 4B
Cdc25A protein degradation occurs in Met-F-AEA treated
cells. In contrast, in the cells treated with Met-F-AEA in pres-
ence of staurosporine, the Cdc25A degradation was inhibited.
These results suggest that Chk1 target Cdc25A for degradation
in response to Met-F-AEA.4. Discussion
Stable endocannabinoids analogues have been proposed as
novel anticancer drugs. In previous studies we reported that
anandamide, through CB1 receptor stimulation, inhibits ras
oncogene-dependent thyroid tumour growth in vitro and
in vivo [5,6]. Moreover, we previously described the antimito-
genic eﬀects of anandamide on several breast cancer cell lines
[3,4,7]. All the observed anti-tumour eﬀects were counteracted
by the selective CB1 receptor antagonist SR141716 [3–7].
Interestingly, we reported that SR141716 besides its antagonistproperties is able to inhibit human breast cancer cell growth
via a CB1 receptor lipid rafts/caveolae-mediated mechanism
[26]. In the present study, we analyzed the cell cycle distribu-
tion of MDA-MB-231 breast cancer cells by ﬂow cytometry
and we founded that Met-F-AEA treatment increased the per-
centage of cells in S phase with a concomitant reduction in G2/
M phase. These ﬁndings provide evidence that the anti-prolif-
erative eﬀect of Met-F-AEA, that we previously observed in
MDA-MB-231 cells [7], results from cell cycle arrest and accu-
mulation in S phase at 24 h, without induction of apoptosis.
We showed that this cell cycle arrest is accompanied with an
induction of p21waf and p27kip1 and a decrease of cyclins A
and E protein levels at 24 h from the Met-F-AEA treatment.
Moreover, we observed an inhibition of cdk2 activity at the
same time point and a decreased cyclin E expression in the
complexes immunoprecipitated with Cdk2 antibody. Thus, it
is highly likely that the S phase arrest occurs as a consequence
of the speciﬁc loss in Cdk2 activity because of the upregulation
of p21waf and a reduced formation of the active complex cyclin
E/Cdk2 kinase (Fig. 5). Moreover, since Rb protein is a direct
substrate of Cdk2 kinase, the decreased Rb phosphorylation
detected in cells 24 h after Met-F-AEA exposure is consistent
with the Cdk2 inhibition (Fig. 5) [27]. We also observed that,
although Met-F-AEA did not aﬀected cyclin D1/Cdk4 expres-
sion, a reduction in Rb phosphorylation at S780, the residue
speciﬁcally targeted by cyclin D1/Cdk4 complexes, was found
in Met-F-AEA treated cells, suggesting that both complexes
contribute to the inhibition of phosphorylation of Rb protein.
Recently, it has been demonstrated that the checkpoint kinase
Chk1 mediates both intra-S and G2 phase checkpoints by tar-
geting the Cdc25A phosphatase to proteolysis following DNA
damage [22–24,28]. Since Cdc25A accumulates at the G1/S
transition, the model of a critical role of Chk1 in preventing
over-accumulation of Cdc25A in an unperturbed cell cycle pre-
dicts that Chk1 is periodically activated in every S phase [29].
The Cdc25A positively regulates the cell cycle by activating
Cdks. In the breast cancer cell line MCF-7, Cdc25A activity
is necessary for both the activation of Cdk2 and subsequent
Fig. 5. Schematic model depicting Met-F-AEA eﬀect on cell cycle machinery in MDA-MB-231 breast cancer cells.
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apeutic target in breast cancer [30]. Interestingly, Cdc25A has
been found overexpressed in a subset of aggressive human can-
cers [31–33]. Regulation of Cdc25A is essential not only for
progression of cells through an unperturbed cell division cycle
but also for cells to arrest in response to checkpoint activation.
The activity and abundance of Cdc25A is regulated by revers-
ible phosphorylation, protein–protein interactions, and ubiqui-
tin-mediated proteolysis. Human Cdc25A is phosphorylated at
several sites in vivo, and Chk1 is required for the majority of
these phosphorylations in vivo during interphase; these events
target Cdc25A for rapid degradation [24]. For the ﬁrst time in
this report we observed that Met-F-AEA activates Chk1 by
arresting cells in S phase through Cdc25A proteolisis, pre-
venting Cdk2 activation by dephosphorylation on critical
inhibitory residues (Thr14/Tyr15), and thus inhibiting cyclin
E-Cdk2 and Cyclin A-Cdk2 complexes. We showed that
Met-F-AEA induced Chk1 phosphorylation and decreased
the level of Cdc25A protein at 24 h. Indeed, when the cells
were treated with Met-F-AEA in the presence of the Chk1
kinase inhibitor, staurosporine (24 h), we observed a decreased
Chk1 phosphorylation and an increased cdc25A protein level.
Interestingly, the Met-F-AEA induced S phase blockade
was prevented by staurosporine co-treatment (data not
shown). Moreover, MDA-MB-231 cells present prerequisites
(overexpression of the proto-oncogenes cyclin E, Cdc25A
and mutated p53) able to activate the ATM/ATR-regulated
DNA damage network. Actually, we are investigating through
what kind of DNA damage Met-F-AEA may activate the S
phase checkpoint. We could speculate that it may be a conse-
quence of a replication stress rather than of a genotoxic action
of Met-F-AEA. In fact when cells experience replicational
stress they activate their replication checkpoint to delay S
phase progression and G2/M transition [34]. Importantly,
none of the S phase checkpoint requires p53, which is the
key target of the G1/S checkpoint that arrests the cell cycle
in G1 [27].
Then we propose that both the transient cell cycle check-
point response (Cdc25A degradation) and the delayed one
(p21waf cascade) are induced by Met-F-AEA and converge
on suppression of Cdk2 activity leading to cell cycle arrest in
human breast cancer cells (Fig. 5). This mechanism of action,
already reported for chemotherapeutic drugs such as gemcita-
bine, a potent radiosensitizer [35], and for diﬀerent topoiso-
merase inhibitors [36], provides strong evidence for a directrole of anandamide related compounds in the activation of cell
cycle checkpoints. This could be of great medical interest since
recent ﬁndings suggest that DNA damage checkpoints might
become activated in the early stages of human tumorigenesis
leading to cell-cycle blockade or apoptosis and could act as a
barrier against cancer and genetic instability, thereby con-
straining tumour progression [37,38].
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